The U.S. drug maker and its partner BioNTech say there are on track to seek regulatory review of their COVID-19 vaccine as early as October 2020 if it is successful in clinical trials.
from rss_headline https://ift.tt/3hl2Iwr
via IFTTT
from rss_headline https://ift.tt/3hl2Iwr
via IFTTT
Kommentare
Kommentar veröffentlichen